Adial Pharmaceuticals (ADIL) Scheduled to Post Earnings on Thursday

Adial Pharmaceuticals (NASDAQ:ADIL) is set to release its earnings data on Thursday, March 28th.

Adial Pharmaceuticals Price Performance

Shares of ADIL opened at $1.37 on Wednesday. Adial Pharmaceuticals has a 1 year low of $0.77 and a 1 year high of $14.00. The company has a 50 day simple moving average of $1.46 and a two-hundred day simple moving average of $1.95. The firm has a market cap of $2.27 million, a P/E ratio of -0.24 and a beta of 1.52.

Institutional Investors Weigh In On Adial Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP grew its holdings in Adial Pharmaceuticals by 144.3% during the 1st quarter. Susquehanna International Group LLP now owns 222,283 shares of the company’s stock valued at $78,000 after buying an additional 131,287 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Adial Pharmaceuticals by 74.6% in the fourth quarter. Renaissance Technologies LLC now owns 251,886 shares of the company’s stock valued at $54,000 after purchasing an additional 107,656 shares in the last quarter. Citadel Advisors LLC grew its holdings in shares of Adial Pharmaceuticals by 1,156.2% in the third quarter. Citadel Advisors LLC now owns 265,062 shares of the company’s stock valued at $93,000 after purchasing an additional 243,962 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Adial Pharmaceuticals in the second quarter valued at $53,000. Finally, Virtu Financial LLC purchased a new position in shares of Adial Pharmaceuticals in the second quarter valued at $43,000. 16.41% of the stock is owned by hedge funds and other institutional investors.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.